Litmys and PharmaACE Team Up to Enhance Life Sciences Decision-Making and Forecasting

Strategic Collaboration to Transform Life Sciences Forecasting

In a groundbreaking partnership, Litmys, a prominent consulting firm specializing in life sciences commercial strategy, and PharmaACE, a leader in analytics for the pharmaceutical sector, have announced a strategic collaboration aimed at enhancing commercial forecasting and decision-making in the life sciences industry. This partnership leverages the unique strengths of both companies to provide life sciences businesses with insights that can significantly inform their commercialization strategies.

Understanding the Core of the Collaboration

Litmys specializes in commercial readiness and adoption analytics. Their expertise lies in comprehending the intricate factors that drive product adoption in real-world scenarios. On the other hand, PharmaACE brings advanced forecasting capabilities and commercial modeling to the table. By merging these two expertise areas, the collaboration seeks to transform how life sciences organizations assess market potential and develop commercial strategies.

Harris Kaplan, Managing Partner at Litmys, emphasizes that understanding the dynamics between physicians, payers, and patients is crucial for driving product adoption. Traditional forecasting methods often fall short by focusing excessively on clinical profiles and market assumptions without considering how these stakeholders interact. The collaboration with PharmaACE aims to address this gap by integrating a stakeholder approach into market forecasting.

Innovative Methodologies for Real-World Application

One of the significant innovations this collaboration introduces is the RAMPx™ methodology by Litmys, which stands for Realistic Assessment of Market Potential. This model evaluates drivers of adoption such as product advantages, barriers to utilization, and changes in stakeholder behavior. PharmaACE enhances this framework with its sophisticated forecasting models that allow clients to create actionable market projections.

Michael Devinoff, Chief Strategy Officer at PharmaACE, elaborates that the most successful forecasts encompass deep understanding, reflecting the realities of market conditions rather than just theoretical projections. The integration of Litmys’ focus on adoption with PharmaACE’s forecasting expertise arms clients with greater confidence in their commercial decisions.

Benefits for Life Sciences Companies

The implications of this partnership are significant for life sciences companies:

1. More Accurate Commercial Forecasts: By incorporating insights into stakeholder adoption with advanced forecasting models, companies can create market projections that align more closely with actual customer behavior.

2. Early Identification of Risks: This collaboration enables organizations to understand potential challenges concerning adoption before finalizing pivotal development and commercialization decisions.

3. Informed Investment Decisions: The synergy between commercial readiness assessments and financial modeling equips life sciences firms with a comprehensive view of an asset’s commercial viability.

4. Integrated Strategic Support: Clients benefit from a wealth of expertise spanning market research, adoption assessments, and commercial analytics, supporting informed decisions across the entire product lifecycle.

The combined efforts of Litmys and PharmaACE aim to offer life sciences clients a streamlined framework to evaluate various opportunities and allocate resources effectively across their portfolios.

About the Companies

Litmys, headquartered in Santa Fe, New Mexico, specializes in assessing risks in drug and device development, helping companies navigate the complexities of commercialization efficiently. Their proprietary methodologies enhance pipeline return on investment by predicting a therapeutic asset's real-world viability early on.

PharmaACE, founded in 2013 and situated in Princeton, New Jersey, provides a wide array of consulting services, particularly in forecasting and market access across several therapeutic areas including oncology and immunology. Their robust analytics capabilities help decision-makers in the pharmaceutical industry tackle critical questions and strategize effectively in the commercialization phase.

Through this strategic collaboration, Litmys and PharmaACE not only aim to enhance forecasting practices but also to pave the way for smarter, more informed commercial strategies that benefit the life sciences sector as a whole.